2
|
Negre Busó M, Estorch Cabrera M, Mitjavila Casanovas M. PET/CT in nuclear endocrinology: Results of the survey diffused through different social networks of the SEMNIM in Spain. Rev Esp Med Nucl Imagen Mol 2023; 42:77-82. [PMID: 36403726 DOI: 10.1016/j.remnie.2022.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2022] [Revised: 09/08/2022] [Accepted: 09/14/2022] [Indexed: 11/18/2022]
Abstract
AIM To know the current use of the PET/CT technology applied in the field of endocrinology, the Endocrinology Working Group of SEMNIM proposed conducting a survey. The objective was to obtain a snapshot of the use of PET/CT in nuclear endocrinology, to know if it is being used properly and detect possible needs. MATERIAL AND METHODS During the first quarter of 2022, we analyzed the data obtained from a survey that was distributed through different social networks throughout the second half of 2021. The survey asked for the use of the different PET/CT techniques available in Spain in different endocrinological pathologies like differentiated thyroid carcinoma, medullary thyroid carcinoma, neuroendocrine tumors and hyperparathyroidism. RESULTS A total of 15 centers responded to the survey. A percentage of 79 of hospitals used 18F-FDG PET/CT in the diagnosis and/or follow-up of differentiated thyroid carcinoma (mean annual studies: 36.9; range 10-100); 85% used 18F-DOPA PET/CT for the study of biochemical recurrence of medullary thyroid carcinoma (mean annual studies: 7.8; range 2-20); 77% used 18F-DOPA PET/CT for the study of neuroendocrine tumors: 77% used 18F-DOPA PET/CT (mean of 10 scans per year; range 2-30) and 69% used 68Ga-DOTA-SA (mean of 24.7 studies per year; range 2-127); 79% used 18F-choline PET/CT for the study of hyperparathyroidism (mean of 30.1 annual studies; range 10-120). CONCLUSIONS We detected that the use of the PET/CT technique in endocrinology is not yet widespread, however, we saw that the indications in which it is used are, in general, those reported in the different consensus.
Collapse
Affiliation(s)
- M Negre Busó
- Servicio de Medicina Nuclear-IDI, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain; Grupo de Trabajo de Endocrinología de la SEMNIM.
| | - M Estorch Cabrera
- Grupo de Trabajo de Endocrinología de la SEMNIM; Servicio de Medicina Nuclear, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
| | - M Mitjavila Casanovas
- Grupo de Trabajo de Endocrinología de la SEMNIM; Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro-Majadahonda, Majadahonda, Madrid, Spain
| | | |
Collapse
|
3
|
Clement SC, Visser WE, Lebbink CA, Albano D, Claahsen-van der Grinten HL, Czarniecka A, Dias RP, Dierselhuis MP, Dzivite-Krisane I, Elisei R, Garcia-Burillo A, Izatt L, Kanaka-Gantenbein C, Krude H, Lamartina L, Lorenz K, Luster M, Navardauskaitė R, Negre Busó M, Newbold K, Peeters RP, Pellegriti G, Piccardo A, Priego AL, Redlich A, de Sanctis L, Sobrinho-Simões M, van Trotsenburg ASP, Verburg FA, Vriens M, Links TP, Ahmed SF, van Santen HM. Development of a pediatric differentiated thyroid carcinoma registry within the EuRRECa project: rationale and protocol. Endocr Connect 2023; 12:e220306. [PMID: 37931414 PMCID: PMC9986407 DOI: 10.1530/ec-22-0306] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/30/2022] [Accepted: 01/10/2023] [Indexed: 10/06/2023]
Abstract
Background Although differentiated thyroid carcinoma (DTC) is the most frequent endocrine pediatric cancer, it is rare in childhood and adolescence. While tumor persistence and recurrence are not uncommon, mortality remains extremely low. Complications of treatment are however reported in up to 48% of the survivors. Due to the rarity of the disease, current treatment guidelines are predominantly based on the results of small observational retrospective studies and extrapolations from results in adult patients. In order to develop more personalized treatment and follow-up strategies (aiming to reduce complication rates), there is an unmet need for uniform international prospective data collection and clinical trials. Methods and analysis The European pediatric thyroid carcinoma registry aims to collect clinical data for all patients ≤18 years of age with a confirmed diagnosis of DTC who have been diagnosed, assessed, or treated at a participating site. This registry will be a component of the wider European Registries for Rare Endocrine Conditions project which has close links to Endo-ERN, the European Reference Network for Rare Endocrine Conditions. A multidisciplinary expert working group was formed to develop a minimal dataset comprising information regarding demographic data, diagnosis, treatment, and outcome. We constructed an umbrella-type registry, with a detailed basic dataset. In the future, this may provide the opportunity for research teams to integrate clinical research questions. Ethics and dissemination Written informed consent will be obtained from all participants and/or their parents/guardians. Summaries and descriptive analyses of the registry will be disseminated via conference presentations and peer-reviewed publications.
Collapse
Affiliation(s)
- S C Clement
- Department of Pediatrics, Emma Children’s Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
- Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital/ University Medical Center Utrecht, Utrecht, The Netherlands
| | - W E Visser
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - C A Lebbink
- Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital/ University Medical Center Utrecht, Utrecht, The Netherlands
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - D Albano
- Department of Nuclear Medicine, University of Brescia and Spedali Civili of Brescia, Brescia, Italy
| | - H L Claahsen-van der Grinten
- Department of Pediatrics, Radboud University Medical Center, Amalia Children's Hospital, Nijmegen, The Netherlands
| | - A Czarniecka
- The Oncologic and Reconstructive Surgery Clinic, M. Sklodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
| | - R P Dias
- Department of Endocrinology and Diabetes, Birmingham Children’s Hospital, Birmingham Women’s, and Children’s NHS Foundation Trust, Birmingham, UK
- Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - M P Dierselhuis
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - I Dzivite-Krisane
- Department of Pediatric Endocrinology, Children's Clinical University Hospital, Riga, Latvia
| | - R Elisei
- Endocrine Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - A Garcia-Burillo
- Nuclear Medicine Department, Vall d'Hebron University Hospital, Barcelona, Spain
| | - L Izatt
- Department of Clinical Genetics, Guy's and St Thomas’ NHS Foundation Trust, London, UK
| | - C Kanaka-Gantenbein
- Division of Endocrinology, Diabetes, and Metabolism, First Department of Pediatrics National and Kapodistrian University of Athens Medical School, Aghia Sophia Children's Hospital, Athens, Greece
| | - H Krude
- Institute of Experimental Pediatric Endocrinology, Charité - Universitätsmedizin, Berlin, Germany
| | - L Lamartina
- Department of Endocrine Oncology, Gustave Roussy, Villejuif, France
| | - K Lorenz
- Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
| | - M Luster
- Department of Nuclear Medicine, University Hospital Marburg, Marburg, Germany
| | - R Navardauskaitė
- Department of Endocrinology, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - M Negre Busó
- Nuclear Medicine Service - Institut de diagnòstic per la Imatge, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Spain
| | - K Newbold
- Thyroid Therapy Unit, The Royal Marsden NHS Foundation Trust Hospital, London, UK
| | - R P Peeters
- Academic Center For Thyroid Disease, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
| | - G Pellegriti
- Endocrinology, Endocrinology Division, Garibaldi-Nesima Medical Center, Catania, Italy
| | - A Piccardo
- Department of Nuclear Medicine, EO Ospedali Galliera, Genoa, Italy
| | - A L Priego
- Department of Medicine, Division of Endocrinology, Leiden, University medical Center, Leiden, The Netherlands
| | - A Redlich
- Pediatric Oncology Department, Otto von Guericke University Children's Hospital, Magdeburg, Germany
| | - L de Sanctis
- Regina Margherita Children Hospital - Department of Public Health and Pediatric Sciences, University of Torino, Torino, Italy
| | - M Sobrinho-Simões
- University Hospital of São João, Medical Faculty and Institute of Molecular Pathology and Immunology, University of Porto, Porto, Portugal
| | - A S P van Trotsenburg
- Department of Pediatric Endocrinology, Emma Children’s Hospital, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - F A Verburg
- Department of Radiology & Nuclear Medicine, Erasmus MC Rotterdam, Rotterdam, The Netherlands
| | - M Vriens
- Department of Endocrine Surgery, University Medical Center Utrecht, Utrecht, The Netherlands
| | - T P Links
- Department of Endocrinology, University Medical Center Groningen, Groningen, The Netherlands
| | - S F Ahmed
- Endocrinology, Endocrinology Division, Garibaldi-Nesima Medical Center, Catania, Italy
- Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK
- Office for Rare Conditions, University of Glasgow, Glasgow, UK
| | - H M van Santen
- Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital/ University Medical Center Utrecht, Utrecht, The Netherlands
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| |
Collapse
|
4
|
Mestre Fusco A, Beltrán Mármol B, Álvarez Bravo G, Ferran Sureda N, Negre Busó M, Rubió Rodríguez A. PET coregistered with MRI imaging of anti-NMDAR encephalitis patient with SARS-CoV-2 infection. Rev Esp Med Nucl Imagen Mol 2021; 41 Suppl 1:S46-S47. [PMID: 34607785 PMCID: PMC8450268 DOI: 10.1016/j.remnie.2021.09.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Accepted: 07/18/2021] [Indexed: 10/25/2022]
Affiliation(s)
- A Mestre Fusco
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, Spain.
| | - B Beltrán Mármol
- Radiología - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, Spain
| | - G Álvarez Bravo
- Neurología, Hospital Universitari Dr. Josep Trueta, Girona, Spain
| | - N Ferran Sureda
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, Spain
| | - M Negre Busó
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, Spain
| | - A Rubió Rodríguez
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, Spain
| |
Collapse
|
7
|
Negre Busó M, Balliu Collgrós E, Rubió Rodríguez A, Peláez Hernández I, Mestre Fusco A, Roncero Vidal JM. Utility of the 18F-FDG PET/CT in the diagnosis of the neurolymphomatosis: A case report. Rev Esp Med Nucl Imagen Mol 2021; 40:328-331. [PMID: 34425977 DOI: 10.1016/j.remnie.2020.09.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2020] [Accepted: 06/30/2020] [Indexed: 11/25/2022]
Affiliation(s)
- M Negre Busó
- Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalunya, Spain.
| | - E Balliu Collgrós
- Servei de Radiologia-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalunya, Spain
| | - A Rubió Rodríguez
- Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalunya, Spain
| | - I Peláez Hernández
- Servei de Radiologia-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalunya, Spain
| | - A Mestre Fusco
- Servei Medicina Nuclear-IDI Girona, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalunya, Spain
| | - J M Roncero Vidal
- Servei Hematologia-ICO Girona, Hospital Universitari de Girona Dr. Josep Trueta, Girona, Catalunya, Spain
| |
Collapse
|
8
|
Mestre Fusco A, Beltrán Mármol B, Álvarez Bravo G, Ferran Sureda N, Negre Busó M, Rubió Rodríguez A. PET coregistered with MRI imaging of anti-NMDAR encephalitis patient with SARS-CoV-2 infection. Rev Esp Med Nucl Imagen Mol 2021; 41:S2253-654X(21)00144-X. [PMID: 34489207 PMCID: PMC8373819 DOI: 10.1016/j.remn.2021.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Revised: 07/17/2021] [Accepted: 07/18/2021] [Indexed: 11/25/2022]
Affiliation(s)
- A Mestre Fusco
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, España.
| | - B Beltrán Mármol
- Radiología - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, España
| | - G Álvarez Bravo
- Neurología, Hospital Universitari Dr. Josep Trueta, Girona, España
| | - N Ferran Sureda
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, España
| | - M Negre Busó
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, España
| | - A Rubió Rodríguez
- Unidad de Medicina Nuclear - IDI Girona, Hospital Universitari Dr. Josep Trueta, Girona, España
| |
Collapse
|